Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency

Pharmacotherapy

Volumn 35, Issue 1, 2015, Pages 64-71

  Reed, Brent N ^a   Blair, Elizabeth A ^b   Thudium, Emily M ^b   Waters, Sarah B ^c   Sueta, Carla A ^c   Jensen, Brian C ^c   Rodgers, Jo E ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Intravenous iron; Iron deficiency; Sodium ferric gluconate

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRITIN; HEMOGLOBIN; HYDRALAZINE; INOTROPIC AGENT; IRON; IRON SACCHARATE; ISOSORBIDE DINITRATE; TRANSFERRIN; ANTIANEMIC AGENT; FERRIC ION;

ABDOMINAL DISCOMFORT; ADULT; AFRICAN AMERICAN; ARTICLE; BACKACHE; BLADDER DISCOMFORT; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CAUCASIAN; CELLULITIS; CHILL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART EJECTION FRACTION; HEART FAILURE; HEART RATE; HEMATOLOGICAL PARAMETERS; HOSPITAL PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; HYPOVOLEMIA; INJECTION SITE DISCOMFORT; INJECTION SITE PRURITUS; IRON DEFICIENCY; LEG CRAMP; MALE; NAUSEA; PILOT STUDY; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TERTIARY CARE CENTER; THROMBOPHLEBITIS; TRANSFERRIN BLOOD LEVEL; VASODILATATION; ANEMIA, IRON-DEFICIENCY; BLOOD; CLINICAL TRIAL; COMPLICATION; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; HEART FAILURE; HEMATINICS; HEMOGLOBINS; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84926194780     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1525     Document Type: Article

References (21)

1. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872-80.
2. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observerblinded trial. J Am Coll Cardiol 2008;51:103-12.
3. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
4. Beavers CJ, Alburikan KA, Rodgers JE, Dunn SP, Reed BN. Distinguishing anemia and iron deficiency of heart failure: signal for severity of disease or unmet therapeutic need? Pharmacotherapy 2014;34:719-32.
5. Wall GC, Pauly RA. Evaluation of total-dose iron sucrose infusions in patients with iron deficiency anemia. Am J Health Syst Pharm 2008;65:150-3.
6. Blaustein DA, Schwenk MH, Chattopadhyay J, et al. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney Int Suppl 2003;87:S72-7.
7. Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970;100:301-3.
8. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006;48(6):1225-7.
9. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007;50(17):1657-65.
10. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008;21(2):236-42.
11. Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003;92:625-8.
12. Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). AmJ Cardiol 2008;101:223-30.
13. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-27.
14. Jankowska EA, von Haehling S, Anker SD, Macdougall IC Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013;34:816-29.
15. Kobashigawa J, Mehra M, West L, et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant 2009;28:213-25.
16. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-82.
17. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001;16:1239-44.
18. Folkert VW, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration. Am J Kidney Dis 2003;41:651-7.
19. Javier AM. Weekly administration of high-dose sodium ferric gluconate is safe and effective in peritoneal dialysis patients. Nephrol Nurs J 2002;29:183-6.
20. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013;368:1210-9.
21. Androne A-S, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226-9.